Acceleron Pharma Inc.
Endoglin polypeptides and uses thereof

Last updated:

Abstract:

In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders.

Status:
Grant
Type:

Utility

Filling date:

28 Feb 2018

Issue date:

20 Apr 2021